Granulocyte-macrophage colony-stimulating factor (GM-CSF) is not recommended in the setting of CAR T-cell therapy in NCCN guideline because CRS was deteriorated by IL-6, IL-1 and nitric oxide produced by recipient macrophages in murine model (11). This evidence concerns the gene CSF2 and congenital rubella syndrome.